Business and Finance

Novo Nordisk is tagged as the only 'high performer'

Effect of the first full year of Obamacare was muted, although a record number of prescriptions were written

Creation of a holding company streamlines future acquisitions; focus is on specialty drug services

More executional capabilities derive from affiliation with parent, inVentiv Health

$2-billion acquisition brings a $5-billion/yr PBM to Rite Aid's 4,600 retail stores

Association's annual specialty-distribution study focuses trend in oncology, chronic diseases

Reporting by pharma companies on spending on physicians is becoming a non-event

Analysis from Prime Therapeutics points to severe cost hurdles for biosimilars developed and marketed in the US

Manufacturers will need to refine their interactions with healthcare providers and produce better outcomes research and adherence programs to compete

Mapi Group casts itself as a leading 'health research and commercialization' player

So long WAG, hello to WBA as pharma manufacturers look at a consolidating buyer landscape

Express Scripts touts a 'fundamental change' in drug pricing; others would call it negotiating a discount

When state and federal governments are involved, prices and reimbursements have both regulatory and financial consequences

A big jump in 2012-2013 venture funding will fuel growth; BMS' new facility

Company is part of limited distribution for a Lundbeck neurologic treatment

Payer trends dominate near-term outlook

Efforts to align drug wholesaling business with manufacturer services

Largest independent specialty pharmacy rides specialty-pharma wave

Vendor-managed system inventories and protects specialty pharmaceuticals in healthcare settings

Pharmaceutical Commerce sat down with Mr. Mortazavi recently; here's what he had to say.

Absence of agreed-on FDA guidance keeps biosimilars off the US market even as their use grows abroad

Battlefield over drug pricing